Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Background: Many patients with asthma have type-2 airway inflammation, identified by the presence of biomarkers, including history of allergy, high blood eosinophil (EOS) count, and high fractional exhaled nitric oxide levels. Objective: To assess disease burden in relation to type-2 inflammatory biomarker status (history of allergy, blood EOS count, and fractional exhaled nitric oxide level) in patients with uncontrolled and controlled severe asthma in the NOVEL observational longiTudinal studY (NOVELTY) (NCT02760329). Methods: Asthma diagnosis and severity were physician-reported. Control was defined using Asthma Control Test score (uncontrolled <20, controlled ≥20) and/or 1 or more severe physician-reported exacerbation in the previous year. Biomarker distribution (history of allergy, blood EOS count, and fractional exhaled nitric oxide level), symptom burden (Asthma Control Test score, modified Medical Research Council dyspnea scale), health status (St George's Respiratory Questionnaire score), exacerbations, and health care resource utilization were assessed. Results: Of 647 patients with severe asthma, 446 had uncontrolled and 123 had controlled asthma. Among those with uncontrolled asthma, 196 (44%) had 2 or more positive biomarkers, 187 (42%) had 1 positive biomarker, 325 (73%) had low blood EOS, and 63 (14%) were triple-negative. Disease burden was similarly high across uncontrolled subgroups, irrespective of biomarker status, with poor symptom control (Asthma Control Test score 14.9-16.6), impaired health status (St George's Respiratory Questionnaire total score 46.7-49.4), clinically important breathlessness (modified Medical Research Council grade ≥2 in 47.3%-57.1%), and 1 or more severe exacerbation (70.6%-76.2%). Conclusions: Type-2 inflammatory biomarkers did not differentiate disease burden in patients with severe asthma. Patients with low type-2 inflammatory biomarker levels have few biologic therapy options; their needs should be addressed.
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers / Ding, B., Chen, S., Rapsomaniki, E., Quinton, A., Cook, W., Reddel, H.K., Papi, A., del Olmo, R., Anderson, G., Reddel, H., Rabahi, M., Mcivor, A., Sadatsafavi, M., Weinreich, U., Burgel, P.-R., Devouassoux, G., Inoue, H., Rendon, A., van den Berge, M., Beasley, R., et al.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE. - ISSN 2213-2198. - 12:4(2024), pp. 970-982. [10.1016/j.jaip.2023.12.021]
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers
Ding B.;Chen S.;Rapsomaniki E.;Quinton A.;Cook W.;Reddel H. K.;Papi A.;del Olmo R.;Anderson G.;Reddel H.;Rabahi M.;McIvor A.;Sadatsafavi M.;Weinreich U.;Burgel P. -R.;Devouassoux G.;Inoue H.;Rendon A.;van den Berge M.;Beasley R.;Garcia-Navarro A. A.;Faner R.;Rivera J. O.;Janson C.;Bilinska-Izydorczyk M.;Fageras M.;Fihn-Wikander T.;Franzen S.;Keen C.;Ostridge K.;Chalmers J.;Harrison T.;Pavord I.;Price D.;Azim A.;Belton L.;Ble F. -X.;Erhard C.;Gairy K.;Hughes R.;Lassi G.;Mullerova H.;Scott I. C.;Chipps B.;Christenson S.;Make B.;Tomaszewski E.;Benhabib G.;Ruiz X. B.;Lisanti R. E.;Marino G.;Mattarucco W.;Nogueira J.;Parody M.;Pascale P.;Rodriguez P.;Silva D.;Svetliza G.;Victorio C. F.;Rolon R. W.;Yanez A.;Baines S.;Bowler S.;Bremner P.;Bull S.;Carroll P.;Chaalan M.;Farah C.;Hammerschlag G.;Hancock K.;Harrington Z.;Katsoulotos G.;Kim J.;Langton D.;Lee D.;Peters M.;Prassad L.;Sajkov D.;Santiago F.;Simpson F. G.;Tai S.;Thomas P.;Wark P.;Delfini Cancado J. E.;Cunha T.;Lima M.;Cardoso A. P.;FitzGerald J. M.;Anees S.;Bertley J.;Bell A.;Cheema A.;Chouinard G.;Csanadi M.;Dhar A.;Dhillon R.;Kanawaty D.;Kelly A.;Killorn W.;Landry D.;Luton R.;Mandhane P.;Pek B.;Petrella R.;Stollery D.;Wang C.;Chen M.;Chen Y.;Gu W.;Christopher Hui K. M.;Li M.;Li S.;Lijun M.;Qin G.;Song W.;Tan W.;Tang Y.;Wang T.;Wen F.;Wu F.;Xiang P.;Xiao Z.;Xiong S.;Yang J.;Yang J.;Zhang C.;Zhang M.;Zhang P.;Zhang W.;Zheng X.;Zhu D.;Bueno C. M.;Grimaldos F. B.;Arboleda A. C.;Molina de Salazar D.;Bendstrup E.;Hilberg O.;Kjellerup C.;Raherison C.;Bonniaud P.;Brun O.;Chouaid C.;Couturaud F.;de Blic J.;Debieuvre D.;Delsart D.;Demaegdt A.;Demoly P.;Deschildre A.;Egron C.;Falchero L.;Goupil F.;Kessler R.;Le Roux P.;Mabire P.;Mahay G.;Martinez S.;Melloni B.;Moreau L.;Riviere E.;Roux-Claude P.;Soulier M.;Vignal G.;Yaici A.;Bals R.;Aries S. P.;Beck E.;Deimling A.;Feimer J.;Grimm-Sachs V.;Groth G.;Herth F.;Hoheisel G.;Kanniess F.;Lienert T.;Mronga S.;Reinhardt J.;Schlenska C.;Stolpe C.;Teber I.;Timmermann H.;Ulrich T.;Velling P.;Wehgartner-Winkler S.;Welling J.;Winkelmann E. -J.;Barbetta C.;Braido F.;Cardaci V.;Clini E. M.;Costantino M. T.;Cuttitta G.;di Gioacchino M.;Fois A.;Foschino-Barbaro M. P.;Gammeri E.;Inchingolo R.;Lavorini F.;Molino A.;Nucera E.;Patella V.;Pesci A.;Ricciardolo F.;Rogliani P.;Sarzani R.;Vancheri C.;Vincenti R.;Endo T.;Fujita M.;Hara Y.;Horiguchi T.;Hosoi K.;Ide Y.;Inomata M.;Inoue K.;Inoue S.;Kato M.;Kawasaki M.;Kawayama T.;Kita T.;Kobayashi K.;Koto H.;Nishi K.;Saito J.;Shimizu Y.;Shirai T.;Sugihara N.;Takahashi K. -I.;Tashimo H.;Tomii K.;Yamada T.;Yanai M.;Rendon A.;Javier R. C.;Peregrina A. D.;Corzo M. F.;Gonzalez E. M.;Ramirez-Venegas A.;Boersma W.;Djamin R. S.;Eijsvogel M.;Franssen F.;Goosens M.;Graat-Verboom L.;Veen J. I.;Janssen R.;Kuppens K.;van de Ven M.;Bakke P.;Brunstad O. P.;Einvik G.;Hoines K. J.;Khusrawi A.;Oien T.;Yoon H. J.;Chang Y. -S.;Cho Y. J.;Hwang Y. I.;Kim W. J.;Koh Y. -I.;Lee B. -J.;Lee K. -H.;Lee S. -P.;Lee Y. C.;Lim S. Y.;Min K. H.;Oh Y. -M.;Park C. -S.;Park H. -S.;Park H. -W.;Rhee C. K.;Yoon H. -K.;Andujar R.;Anoro L.;Garcia M. B.;Mozo P. C.;Campos S.;Maldonado F. C.;Martinez M. C.;Serrano C. C.;Casanova L. C.;Corbacho D.;Del Campo Matias F.;Echave-Sustaeta J.;Corral G. F.;Setien P. G.;Clemente M. G.;Nunez I. G.;Robaina J. G.;Salmones M. G.;Marin Trigo J. M.;Fernandez M. N.;Palomo S. N.;Perez de Llano L.;Bastida A. P.;Rano A.;Gonzalez-Moro J. R.;Reig A. R.;Garrido J. V.;Curiac D.;Lif-Tiberg C.;Luts A.;Rahlen L.;Rustscheff S.;Adams F.;Bradman D.;Broughton E.;Cosgrove J.;Flood-Page P.;Fuller E.;Hartley D.;Hattotuwa K.;Jones G.;Lewis K.;McGarvey L.;Morice A.;Pandya P.;Patel M.;Roy K.;Sathyamurthy R.;Thiagarajan S.;Turner A.;Vestbo J.;Wedzicha W.;Wilkinson T.;Wilson P.;Al-Asadi L. A.;Anholm J.;Averill F.;Bansal S.;Baptist A.;Campbell C.;Campos M. A.;Crook G.;DeLeon S.;Eid A.;Epstein E.;Fritz S.;Harris H.;Hewitt M.;Holguin F.;Hudes G.;Jackson R.;Kaufman A.;Kaufman D.;Klapholz A.;Krishna H.;Lee D.;Lin R.;Maselli-Caceres D.;Mehta V.;Moy J. N.;Nwokoro U.;Parikh P.;Parikh S.;Perrino F.;Ruhlmann J.;Sassoon C.;Settipane R. A.;Sousa D.;Sriram P.;Wachs R.
2024
Abstract
Background: Many patients with asthma have type-2 airway inflammation, identified by the presence of biomarkers, including history of allergy, high blood eosinophil (EOS) count, and high fractional exhaled nitric oxide levels. Objective: To assess disease burden in relation to type-2 inflammatory biomarker status (history of allergy, blood EOS count, and fractional exhaled nitric oxide level) in patients with uncontrolled and controlled severe asthma in the NOVEL observational longiTudinal studY (NOVELTY) (NCT02760329). Methods: Asthma diagnosis and severity were physician-reported. Control was defined using Asthma Control Test score (uncontrolled <20, controlled ≥20) and/or 1 or more severe physician-reported exacerbation in the previous year. Biomarker distribution (history of allergy, blood EOS count, and fractional exhaled nitric oxide level), symptom burden (Asthma Control Test score, modified Medical Research Council dyspnea scale), health status (St George's Respiratory Questionnaire score), exacerbations, and health care resource utilization were assessed. Results: Of 647 patients with severe asthma, 446 had uncontrolled and 123 had controlled asthma. Among those with uncontrolled asthma, 196 (44%) had 2 or more positive biomarkers, 187 (42%) had 1 positive biomarker, 325 (73%) had low blood EOS, and 63 (14%) were triple-negative. Disease burden was similarly high across uncontrolled subgroups, irrespective of biomarker status, with poor symptom control (Asthma Control Test score 14.9-16.6), impaired health status (St George's Respiratory Questionnaire total score 46.7-49.4), clinically important breathlessness (modified Medical Research Council grade ≥2 in 47.3%-57.1%), and 1 or more severe exacerbation (70.6%-76.2%). Conclusions: Type-2 inflammatory biomarkers did not differentiate disease burden in patients with severe asthma. Patients with low type-2 inflammatory biomarker levels have few biologic therapy options; their needs should be addressed.
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers / Ding, B., Chen, S., Rapsomaniki, E., Quinton, A., Cook, W., Reddel, H.K., Papi, A., del Olmo, R., Anderson, G., Reddel, H., Rabahi, M., Mcivor, A., Sadatsafavi, M., Weinreich, U., Burgel, P.-R., Devouassoux, G., Inoue, H., Rendon, A., van den Berge, M., Beasley, R., et al.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE. - ISSN 2213-2198. - 12:4(2024), pp. 970-982. [10.1016/j.jaip.2023.12.021]
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/991310
Citazioni
ND
10
9
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.
